Jun 18 |
CEL-SCI Presents Head & Neck Cancer Data at Iddst Annual Congress in Budapest: Risk of Death Cut in Half for Patients Treated With Multikine in the Target Population
|
Jun 6 |
Dr. Giovanni Selvaggi, Who Has Brought Several Oncology Drugs to Market, Joins CEL-SCI as Clinical Advisor
|
May 16 |
Cel-Sci GAAP EPS of -$0.28 misses by $0.15
|
May 16 |
CEL-SCI Corporation Reports Second Quarter Fiscal 2024 Financial Results
|
May 8 |
CEL-SCI gains as FDA greenlights confirmatory study for Multikine
|
May 8 |
CEL-SCI Receives FDA Go-Ahead for Its Confirmatory Study of Multikine in the Treatment of Head & Neck Cancer
|
Apr 23 |
CEL-SCI Appoints Mario Gobbo to Its Board of Directors
|
Mar 19 |
CEL-SCI’s LEAPS Vaccine Offers Promising New Paradigm to Treat Rheumatoid Arthritis: Published in Frontiers in Immunology
|
Mar 6 |
CEL-SCI Corporation Issues Letter to Shareholders
|
Feb 15 |
Cel-Sci GAAP EPS of -$0.14
|